Stoke Therapeutics (STOK) Revenue & Revenue Breakdown
Stoke Therapeutics Revenue Highlights
Latest Revenue (Y)
$36.55M
Latest Revenue (Q)
$10.63M
Main Segment (Y)
License
Stoke Therapeutics Revenue by Period
Stoke Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $36.55M | 316.34% |
| 2023-12-31 | $8.78M | -29.22% |
| 2022-12-31 | $12.40M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Stoke Therapeutics generated $36.55M in revenue during NA 2024, up 316.34% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Stoke Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $10.63M | -23.05% |
| 2025-06-30 | $13.82M | -91.29% |
| 2025-03-31 | $158.57M | 601.20% |
| 2024-12-31 | $22.61M | 362.08% |
| 2024-09-30 | $4.89M | 1.30% |
| 2024-06-30 | $4.83M | 14.59% |
| 2024-03-31 | $4.22M | 50.46% |
| 2023-12-31 | $2.80M | -15.30% |
| 2023-09-30 | $3.31M | -233.33% |
| 2023-06-30 | $-2.48M | -148.16% |
| 2023-03-31 | $5.15M | 57.60% |
| 2022-12-31 | $3.27M | 12.53% |
| 2022-09-30 | $2.90M | -10.09% |
| 2022-06-30 | $3.23M | 7.70% |
| 2022-03-31 | $3.00M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Stoke Therapeutics generated $10.63M in revenue during Q3 2025, up -23.05% compared to the previous quarter, and up 220.08% compared to the same period a year ago.
Stoke Therapeutics Revenue Breakdown
Stoke Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| License | $29.40M |
| Service | $7.20M |
Latest
Stoke Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (80.33%), and Service (19.67%).
Stoke Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVAX | Novavax | $682.16M | $70.44M |
| BCRX | BioCryst Pharmaceuticals | $450.71M | $159.40M |
| ARDX | Ardelyx | $333.62M | $110.33M |
| WVE | Wave Life Sciences | $108.30M | $7.61M |
| STOK | Stoke Therapeutics | $36.55M | $10.63M |
| ZBIO | Zenas BioPharma | $5.00M | - |
| UPB | Upstream Bio | $2.37M | $683.00K |
| NTLA | Intellia Therapeutics | - | $13.78M |
| ZYME | Zymeworks | - | $48.73M |
| PHVS | Pharvaris | - | - |
| SYRE | Spyre Therapeutics | - | - |